The new formulation contains the lowest optimal concentration of lactate in culture media available commercially. Studies show that culture media with lower lactate concentrations maintain efficient metabolic rates in embryo culture for in vitro fertilization applications.
Continuous Single Culture -NX was tested for efficacy in human clinical studies where it demonstrated an increase in blastocyst formation rates.
Continuous Single Culture media are available in two forms; ready-to-use, pre-supplemented with HSA or without protein supplementation.
Continuous Single Culture media are designed for fertilization and embryo culture through day 5/6 of embryo development.
Irvine Scientific, a member of JXTG Group, provides cell culture media, reagents, and medical devices for researchers and clinicians working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines.
The company operates dual cGMP manufacturing facilities in California, and Tokyo, Japan.
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment